1200 BRICKELL AVENUE, MIAMI, FL
Reports Positive 7-Day Dog Study Results for SKNY-1—Obesity Treatment Designed to Preserve Lean Body Mass
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
Reports Successful Formulation Results for SKNY-1, its Oral Drug Candidate for Obesity and Addiction
Reg. FD
Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Appointment of Andriy Mushak as Fractional CFO; Alan Weichselbaum Departs
Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
Q2
Q3
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-1
Definitive Proxy Statement
Additional Proxy Materials
Definitive Merger Proxy Statement
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
PREM14A
Submission Upload
Correspondence
Prospectus Filed Pursuant to Rule 424(b)(1)